Skip to content

Neurocognitive Follow-Up (FU) Study

Neurocognitive Scores of Predominantly Formula Fed Preterm Infants in Early Childhood Years

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04962035
Enrollment
21
Registered
2021-07-14
Start date
2021-03-26
Completion date
2021-12-22
Last updated
2023-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive Developmental Delay

Brief summary

This is a follow-up study of a recently completed trial (17.14.INF) evaluating the growth of pre-term infants. Enrolled children will undergo neurocognitive assessments at 18- and 24-months of corrected age (CA).

Detailed description

This is a follow-up study of a recently completed multi-center, prospective, single-arm, open-label interventional trial (17.14.INF - Alprem RTF: NCT03728764) evaluating the growth of pre-term infants receiving a two-stage PTF feeding system while in the neonatal care unit and continuing until 30 days post-discharge. Enrolled children will undergo neurocognitive assessments at 18- and 24-months of corrected age (CA). The timing of the cognitive assessments aligns with routine check-up visits and reflect the period at which developmental delays may first become evident.

Interventions

OTHERNeurocognitive Follow-up

Standard clinical and parent-reported outcomes on cognitive development, temperament and overall health conditions.

Sponsors

Société des Produits Nestlé (SPN)
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
17 Months to 25 Months
Healthy volunteers
Yes

Inclusion criteria

1. Infants / children born prematurely who were enrolled into the original clinical trial and who are less than 24 m of CA. 2. Having obtained his / her parents' (or his or her legally accepted guardian written informed consent and having evidence of personally signed and dated informed consent document indicating that the child's parent(s) / legal guardian has been informed of all pertinent aspects of the study.

Exclusion criteria

1\. Infants identified retrospectively as not meeting the inclusion or

Design outcomes

Primary

MeasureTime frameDescription
Bayley-III scores at 24 months24 months of CABayley Scales of Infant and Toddler Development, third edition (Bayley-III) cognitive score at 24 months of corrected age (CA). Composite scores range 40-160, with a mean of 100 and SD of 10 points. A composite score of 70 or less is an indication of a delay in child neurocognitive development.

Secondary

MeasureTime frameDescription
WeightAt enrollment, 18 and 24 months of CAChild weight (g)
Length/heightAt enrollment, 18 and 24 months of CAChild length/height (cm)
Head circumferenceAt enrollment, 18 and 24 months of CAChild head circumference (cm)
Bayley-III scores at 18 months18 months of CABayley Scales of Infant and Toddler Development, third edition (Bayley-III) cognitive score at 18 months of corrected age (CA). Composite scores range 40-160, with a mean of 100 and SD of 10 points. A composite score of 70 or less is an indication of a delay in child neurocognitive development.
Developmental Milestone scoresAt 18 and 24 months of CAParent-reported achievements of specific age-appropriate milestones (yes/no responses to child performing specific milestones or not)
Number of healthcare usageAt 18 and 24 months of CARetrospective parent-reported recall of the number of healthcare usage and hospitalizations
Feeding patternsAt 18 and 24 months of CAFeeding practice outcomes collected retrospectively at each visit via a parent-reported questionnaire related to breastfeeding duration, prevalence of formula feeding, and age at initiation of complementary feeding
Child temperament scoresAt 18 and 24 months of CAParent-reported child temperament questionnaire validated specifically for children between the ages of 18 and 36 months

Countries

Poland, Slovakia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026